| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T3917 |
10-87 |
Protein |
denotes |
divided into two groups: vehicle (saline)-treated and soluble TNFp55 receptor |
| T3934 |
10-87 |
Regulation |
denotes |
divided into two groups: vehicle (saline)-treated and soluble TNFp55 receptor |
| T3930 |
44-50 |
Entity |
denotes |
saline |
| T3921 |
90-93 |
Protein |
denotes |
TNF |
| T3920 |
109-141 |
Protein |
denotes |
Sigma-Aldrich Co., St. Louis, MO |
| T3919 |
159-176 |
Protein |
denotes |
The dosage of sTN |
| T3922 |
230-317 |
Protein |
denotes |
SE of comparable severity in 100% of animals with 5% mortality in the preliminary study |
| T3932 |
522-544 |
Entity |
denotes |
a brain infusion kit 1 |
| T3928 |
661-694 |
Entity |
denotes |
position with bregma as reference |
| T3926 |
748-764 |
Entity |
denotes |
The infusion kit |
| T3925 |
999-1019 |
Entity |
denotes |
the dose of sTNFp55R |
| T3933 |
1012-1015 |
Protein |
denotes |
TNF |
| T3929 |
1174-1176 |
Entity |
denotes |
SE |
| T3931 |
1300-1308 |
Protein |
denotes |
of TNF-α |
| T3918 |
1314-1332 |
Protein |
denotes |
3 days prior to SE |
| T3923 |
1336-1393 |
Entity |
denotes |
4 days after SE when the volume of vasogenic edema peaked |
| R3027 |
T3917 |
T3934 |
themeOf |
divided into two groups: vehicle (saline)-treated and soluble TNFp55 receptor,divided into two groups: vehicle (saline)-treated and soluble TNFp55 receptor |
